Dr. Nipun B. Merchant, MD

Dr. Merchant practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Merchant's NPI, 1174607279, was assigned on October 25, 2006. Dr. Merchant graduated from SUNY Downstate Health Sciences University in 1990. Dr. Merchant holds Florida license ME122685.

Dr. Merchant's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Merchant's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Merchant practices. Vendor and product names are available with a free account.

Surgical oncology is Dr. Merchant's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Merchant is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Merchant's licenses on file in 5 states: Florida, Tennessee, Maryland, New York and Pennsylvania.

CMS data shows 16 Medicare services from Dr. Merchant across 1 procedure code in 2024, all of them office visits, for 35 Medicare patients. Medicare paid $1,307 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Merchant in 2024. The largest group is 65 to 74, with 16 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Merchant's median patient age at 73, with 41% women.

In 2024, Dr. Merchant wrote 58 Medicare Part D claims for 18 patients. 64% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $33,523 in total drug cost. In 2020, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Merchant for performance year 2024, reported as part of a group. Dr. Merchant accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Merchant as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 181 papers to Dr. Merchant, published from 2006 to 2025. 2022 was the busiest year, with 14. The most frequent topics are Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal and Adenocarcinoma. Dr. Merchant has published most often in Ann Surg Oncol. Dr. Merchant's most frequent co-authors are Jashodeep Datta, MD, Alexander Ashish Parikh, MD, MPH and Syed Arif Ahmad, MD.

Dmand AI links Dr. Merchant to 4 clinical trials. 3 are still active or recruiting. Conditions studied include Adenomatous Polyps, Genetic Predisposition to Disease and Pancreatic Cyst.

CMS Open Payments shows 71 general payments to Dr. Merchant from 21 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 71% of the total. Swedish Orphan Biovitrum AB paid the most, $8,858.

Dmand AI lists 3 awards for Dr. Merchant, most recently Regional Top Doctor in 2014.

Dr. Merchant graduated from SUNY Downstate Health Sciences University in 1990. Dr. Merchant is a member of ACS and ASCO.

Dr. Merchant is in network with 10 carriers, including Elevance, Aetna and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.